A split-face comparison study of pulsed 532-nm KTP laser and 595-nm pulsed dye laser in the treatment of facial telangiectasias and diffuse telangiectatic facial erythema.
OBJECTIVE
Pulsed 595 nm and 532 nm lasers can effectively diminish or eliminate facial telangiectasia. We performed a split-face, single-blind, controlled, comparison study in an effort to determine their individual and comparative efficacy.


METHODS
Fifteen patients were treated using a 595-nm PDL on one side of the face and a pulsed 532-nm potassium-titanyl-phosphate (KTP) laser on the other. Each subject was evaluated at 3 weeks after three treatments.


RESULTS
Both devices improved telangiectasia. The 532-nm device, however, was at least as effective or more effective than the 595-nm laser in all subjects. On average, the KTP laser achieved 62% clearing after the first treatment and 85% clearing 3 weeks after the third treatment, compared to 49% and 75% for the PDL, respectively. Seventy-nine percent of KTP laser-treated patients continued to have swelling for greater than 1 day versus 71% of PDL-treated patients. Of those patients who noted persistent erythema for at least 1 day after treatment, 58% noted more erythema on the KTP laser-treated side compared to 8% on the PDL-treated side.


CONCLUSIONS
Both the 595-nm and the 532-nm pulsed lasers are highly effective in the treatment of facial telangiectasia and redness. The 532-nm KTP laser appears to be more effective but causes more swelling and erythema.
Uebelhoer
Nathan S
NS
Department of Dermatology, Division of Laser Surgery, Naval Medical Center San Diego, CA 92134, USA. nsuebelhoer@nmcsd.med.navy.mil
Bogle
Melissa A
MA
Stewart
Brigitte
B
Arndt
Kenneth A
KA
Dover
Jeffrey S
JS
D000328:Adult; D000368:Aged; D004890:Erythema / Q000532:radiotherapy*; D005148:Facial Dermatoses / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D028022:Low-Level Light Therapy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D013684:Telangiectasis / Q000532:radiotherapy*